tiprankstipranks
Trending News
More News >
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Hong Kong Market
Advertisement

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Revenue

Compare
2 Followers

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Revenue

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had a revenue of 44.01M in the quarter ending Jun 30, 2025, with -44.16%. This bring the company's revenue in the last twelve months to 122.83M, Decreased 54.43%. In the fiscal year ending Dec 31, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had annual revenue of 74.15M with 19109.59% growth.
Revenue (ttm)
122.83M
Revenue Growth
29639.67%
P/S Ratio
156.38
Revenue/Employee
HK$475,314
Employees
156
Market Cap
HK$11.60B

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
74.15M73.76M+19,209.64%
Dec 31, 2023
386.00K-5.30M+6.78%
Dec 31, 2022
5.69M-8.12M+41.21%
Dec 31, 2021
13.81M
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis